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Conventional karyotyping is essential standard practice in the initial evaluation of
myelodysplastic syndrome (MDS) and is the most impactful single component of the
Revised International Prognostic Scoring System (IPSS-R). While single nucleotide
polymorphism array (SNP-A) has demonstrated the ability to detect chromosomal
defects with greater sensitivity than conventional karyotype, widespread adoption is
limited by the unknown additional prognostic impact of SNP-A analysis. Here, we
investigate the significance of additional SNP-A abnormalities in the setting of MDS
and demonstrate differences in survival of patients with additional abnormalities,
even those initially characterized as relatively lower risk either by cytogenetic score
or IPSS-R. Our findings identify specific abnormalities, particularly KMT2A partial tan-
dem duplication, that are invisible to conventional karyotype and potentially contrib-
ute to the poor prognosis of MDS patients. Furthermore, these results demonstrate
the added value of SNP-A analysis in identifying patients who may benefit from more
aggressive therapy, particularly those who would otherwise be classified into lower
risk categories.
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1 | INTRODUCTION
Prognostic classification of myelodysplastic syndrome (MDS) relies
heavily on cytogenetic abnormalities and is currently utilized to
guide therapeutic decision making, including identifying appropriate
candidates for bone marrow transplantation. Indeed, cytogenetic
risk is the most heavily weighted component of the Revised Interna-
tional Prognostic Scoring System (IPSS-R), which categorizes
patients into multiple risk groups of ascending associated poor prog-
nosis.1 While conventional karyotype is the gold standard for detec-
tion of genomic abnormalities in both diagnostic and prognostic
settings, single nucleotide polymorphism arrays (SNP-As) have
emerged as potential means of further categorizing prognostic risk
beyond traditional karyotyping in many hematologic malignancies
due to the assay's greater sensitivity in detecting unbalanced chro-
mosomal defects and copy-neutral loss of heterozygosity (CN-
LOH).2-6 However, widespread adoption and incorporation into
prognostic algorithms has not yet occurred despite evidence of the
clinical significance of SNP-A in combination with already
established karyotypic features.5-8 We therefore sought to refine
our understanding of the significance of additional SNP-A abnormal-
ities and their impact on prognosis and ultimately risk of death. In
particular, given the high frequency of MDS cases showing a normal
karyotype,9,10 we were especially interested in the potential impact
of SNP-A in this group of patients.Sarah M. Choi and Steven B. Van Norman contributed equally to this study.
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2 | MATERIALS AND METHODS
This study was approved by the Institutional Review Board of the Uni-
versity of Michigan. We retrospectively reviewed 108 consecutive
patients who underwent karyotyping and Thermo Fisher Cytoscan™
array (SNP-A) analysis11 for diagnosis/classification of a suspected
myeloid neoplasm and identified 77 patients with a diagnosis of de
novo MDS, excluding therapy-related cases. Among these, we identi-
fied cases for which additional abnormalities were detected by SNP-A
analysis that were not identified using conventional karyotype. We
reviewed each patient's electronic medical record including laboratory
values at diagnosis (hemoglobin, absolute neutrophil count [ANC],
platelet count, and bone marrow blast percentage). We then com-
pared overall survival (OS) based on the presence or absence of addi-
tional cytogenomic abnormalities detected by SNP-A on groups that
were stratified by cytogenetic risk and IPSS-R score (Figure 1). OS
was calculated from date of diagnosis to date of death, censoring for
patients alive at the completion of the study. Patients with both low-
risk karyotype (very good-intermediate cytogenetic risk group) and
consistent SNP-A results were compared to patients with similar low-
risk karyotype but with additional SNP-A abnormalities. These groups
were also stratified by the IPSS-R, and survival was compared in
patients with and without additional SNP-A abnormalities. Unpaired t,
Mann-Whitney, Chi-Square, and Fisher's tests were used as applicable
to compare differences in characteristics between groups with and
without additional abnormalities. Log-rank (Mantle-Cox) test was used
to compare OS between the groups.
3 | RESULTS AND DISCUSSION
Of the 77 patients for whom both karyotype and SNP-A were per-
formed (Table 1), 36 cases had additional abnormalities detected by
SNP-A (47% of all cases; Table 2; Figure 2). Follow-up time ranged
from 1.5 to 85 months (Table 1). Deletions were the most common
finding (29 instances), followed by CN-LOH (19 instances). The most
prevalent single abnormality detected was KMT2A(MLL) partial tan-
dem duplication (KMT2A-PTD) (five cases). Additional abnormalities
included cryptic deletions involving TET2 (3), RUNX1 (2), and CUX1 (1).
SNP-A detected a monosomy 7 in two cases whose conventional
cytogenetics showed a normal karyotype after examining adequate
number of metaphase cells.
Cases with and without additional SNP-A abnormalities showed
similar overall distribution of morphologic categorization and no sta-
tistically significant differences in hemoglobin, ANC, platelet count,
bone marrow blast percentage, or IPSS-R (Table 1; Figure S1).
Among matched cases with very good-intermediate cytogenetic
risk, those that had additional abnormalities detected on SNP-A
showed worse OS (median 35.4 months) than those that did not have
additional abnormalities (median survival not reached; Figure 3A;
P = 0.010). Similar observations were seen when cases were stratified
into matching IPSS-R categories, where very low-intermediate risk
cases with additional SNP-A abnormalities showed worse OS (median
35.4 months) similar to cases of high-very high risk (median
31.3 months) compared to very low-intermediate risk cases
without additional SNP-A abnormalities (median 62.6 months;
Figure 3B; P = 0.020).
F IGURE 1 Study design. MDS cases for which both karyotyping and cytogenomic array (SNP-A) was performed were stratified by
(a) cytogenetic risk and (b) Revised International Prognostic Scoring System (IPSS-R). They were then further stratified based on the presence or
absence of additional SNP-A abnormalities. Survival analysis was performed. MDS, myelodysplastic syndrome; SNP-A, single nucleotide
polymorphism array [Color figure can be viewed at wileyonlinelibrary.com]
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TABLE 1 Clinical characteristics of study group
Total
Cytogenetic risk group













Number of patients 77 33 26 8 10
Age 66 (59-74) 71 (64-78) 0.18 64.4 (60.6-75.5) 71.2 (62.9-80.0) 0.36
Sex 77 0.59 0.64
Male 50 20 18 6 6
Female 27 13 8 2 4
Initial diagnosis 77 0.29 0.46
MDS-SLD 8 3 4 1 0
MDS-MLD 35 17 10 4 4
MDS-EB1 12 6 2 2 2
MDS-EB2 22 7 10 1 4
IPSS-R 3 (2.5-4.9) 2.75 (1.5-4.25) 0.16 6 (4.25-7.6) 7.25 (6-8.5) 0.14
ANC, k/μL 1.6 (0.8-3.4) 1.7 (1.0-2.5) 0.79 0.9 (0.3-2.3) 0.8 (0.5-1.4) 0.85
Hgb, g/dL 9.8 (8.1-11.5) 9.6 (8.0-10.9) 0.73 9.0 (7.6-9.9) 9.1 (8.0-9.5) 0.56
Plt, k/μL 75.5 (53-191) 118 (66-180) 0.6 65 (30-110) 43 (18-59) 0.37
BM blast percent, % 2.3 (0.9-6.1) 2.0 (1.0-4.3) 0.95 1.8 (0.3-6.7) 3.4 (1.3-9.8) 0.24
Therapy 0.8 NA
Supportive 15 12 2 4
Hypomethylating agent 18 12 5 7
Transplant 9 5 3 0
Other 5 6 0 0
Median follow up time, months 32.6 26.5 21.7 7.2
IPSS-R













Number of patients 77 26 20 18 13
Age 67.9 (59.7-75.0) 74.0 (62.8-79.8) 0.22 62.5 (59.5-71.4) 69.1 (65.4-76.3) 0.14
Sex 77 0.35 >0.99
Male 50 15 15 12 8
Female 27 11 5 6 5
Initial diagnosis 77 0.16 0.69
MDS-SLD 8 5 3 0 0
MDS-MLD 35 16 11 4 4
MDS-EB1 12 4 1 5 2
MDS-EB2 22 1 5 9 7
IPSS-R 2.75 (2-3.5) 2 (1.5-3) 0.3 6 (5.5-6.5) 6.25 (5.6-7.9) 0.3
ANC, k/μL 1.6 (0.8-3.3) 2 (1.1-2.6) 0.37 1.2 (0.4-3.1) 0.9 (0.5-1.9) 0.83
Hgb, g/dL 10.1 (8.6-12.3) 10.1 (8.1-11.3) 0.66 8.3 (7.5-9.8) 9.0 (7.6-9.4) 0.86
Plt, k/μL 87.5 (69.5-164) 118 (69.8-189) 0.62 44 (28-81) 45 (24-122) 0.98
BM blast percent, % 1.6 (0.6-2.5) 1.9 (0.8-2.1) 0.77 8 (1.5-10) 7.4 (2.1-12) 0.58
Therapy 0.99 0.19
(Continues)
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On the contrary, in cases with either poor-very poor cytogenetic
risk or high-very high IPSS-R score, the presence of additional SNP-A
abnormalities did not show a statistically significant impact on OS
though a trend toward poorer survival was observed (Figures 3A,
P = 0.054 and Figures 3B, P = 0.052). This finding suggests that the
prognostic impact of SNP-A abnormalities may be primarily concen-
trated in cases that would otherwise be classified as lower risk either
by cytogenetic score or IPPS-R.
We questioned whether or not incorporating additional SNP-A
findings would impact the calculated IPSS-R. Taking into consideration
cases with anomalies that were greater than 5 Mb excluding CN-LOH
and small focal deletions and gains, only two cases changed IPSS-R
(one from very low to intermediate; one from very low to low). In
terms of our analysis, therefore, there was no impact on survival.
Based on our previous observation of a small cohort of low-risk
MDS cases of KMT2A-PTD which showed poor OS,12 we questioned
whether this single abnormality could be responsible for the survival
differences of the cases with additional SNP-A abnormalities. When
KMT2A-PTD cases were excluded from the analysis, the effects of
additional SNP-A abnormalities when stratifying patients according to
cytogenetic risk and IPSS-R were somewhat abrogated. A trend
toward poorer survival was still noticeable, but no longer statistically
significant (Figure 4A; P = 0.069 and Figure 4B; P = 0.063). Conse-
quently, KMT2A-PTD may be at least partly responsible for the worse
survival seen in patients with additional SNP-A abnormalities and oth-
erwise very good-intermediate cytogenetic risk or very low-
intermediate IPSS-R, though other abnormalities may also contribute
to a lesser extent. Genomic locations of KMT2A-PTD in five cases are
shown in Figure 5.
To summarize, our findings suggest that the presence of additional
SNP-A abnormalities, detected in almost half of MDS cases, has fur-
ther impact on prognosis and OS than that afforded by conventional
karyotype analysis. Cases identified as very good-intermediate cyto-
genetic risk that have additional SNP-A abnormalities demonstrate OS
approaching that of patients with poor-very poor cytogenetic risk.
Similarly, cases identified as very low-intermediate risk by IPSS-R
demonstrate OS more similar to patients with high-very high risk by
IPSS-R. Although a significant component of these differences may be
TABLE 1 (Continued)
IPSS-R













Supportive 14 10 3 6
Hypomethylating agent 13 9 10 10
Transplant 5 3 7 2
Other 4 3 1 3
Median follow up time, months 46.2 26.5 24.2 10.3
Note: Median value (25th-75th percentile) displayed; “Other” therapy (therapies not listed above).
Abbreviations: ANC, absolute neutrophil count; BM, bone marrow; Hgb, hemoglobin; IPSS-R, Revised International Prognostic Scoring System; NA, unable
to perform; Plt, platelet count; SNP-A, single nucleotide polymorphism array.
F IGURE 2 Frequency of additional SNP-A
abnormalities. The number of instances of each
type of additional abnormality, which were not
detected by conventional karyotype, is depicted
for each chromosome. CN-LOH, copy-neutral loss
of heterozygosity; SNP-A, single nucleotide
polymorphism array [Color figure can be viewed
at wileyonlinelibrary.com]































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































770 CHOI ET AL.
F IGURE 3 The presence of additional SNP-A abnormalities negatively impacts survival in patients with very good-intermediate cytogenetic
risk and very low-intermediate IPSS-R. Survival analysis of patients stratified by cytogenetic risk (A; P < 0.0001) and by IPSS-R (B; P = 0.002) was
performed comparing cases with and without additional SNP-A abnormalities. A, Cases with very good-intermediate cytogenetic risk with
additional SNP-A abnormalities showed worse overall survival than those that did not have additional abnormalities (P = 0.010; black and red
groups). SNP-A abnormalities had no statistically significant survival impact in cases with poor-very poor cytogenetic risk (P = 0.054; green and
blue groups). B, Very low-intermediate IPSS-R cases with additional SNP-A abnormalities showed worse overall survival compared to those
without additional abnormalities (P = 0.020; black and red groups). SNP-A abnormalities had no statistically significant survival impact in cases
with high-very high IPSS-R score (P = 0.052; green and blue groups). IPSS-R, Revised International Prognostic Scoring System; SNP-A, single
nucleotide polymorphism array [Color figure can be viewed at wileyonlinelibrary.com]
F IGURE 4 KMT2A-PTD significantly impacts survival of patients with additional SNP-A abnormalities. A, Patients with very good-
intermediate karyotype showed worse survival in the presence of additional SNP-A abnormalities (P = 0.010), an effect which was abrogated but
not completely eliminated when cases of KMT2A-PTD were excluded (P = 0.069). B, Similar survival effects were seen in cases with very low-
intermediate IPSS-R with (P = 0.020) and without (P = 0.063) KMT2A-PTD. IPSS-R, Revised International Prognostic Scoring System; KMT2A-
PTD, KMT2A partial tandem duplication; SNP-A, single nucleotide polymorphism array [Color figure can be viewed at wileyonlinelibrary.com]
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accounted for by the presence of KMT2A-PTD, the data imply that
other additional abnormalities also impact the prognosis of MDS.
Although the types of abnormalities we noted in our study were
largely similar to those reported in previous studies analyzing SNP-A
in MDS patients,4-7 the frequency of additional SNP-A abnormalities
in our study of 47% was higher than previous reports, which showed
a range of 18% to 39% of cases with additional SNP-A abnormalities.
The increased frequency we observed could potentially be due to
higher resolution of our array platform and as well as our analysis.
Coincident with this observation, KMT2A-PTD was only rarely
reported in these prior studies, whereas in our study this abnormality
was the most common additional SNP-A abnormality observed.
The data also demonstrate that the effect of additional SNP-A
abnormalities is particularly profound in cases that have very good-
intermediate karyotypic features or cases of otherwise low-
intermediate risk by IPSS-R. Thus, the SNP-A may be more effectively
utilized in these particular cases and, perhaps not surprisingly, is more
limited in usefulness in cases that already have definitive poor risk
features. Moreover, because a large proportion of cases in the very
low-intermediate risk/very good-intermediate cytogenetic groups are
patients with a normal karyotype, SNP-A is a potentially useful tool in
further delineating risk subgroups within this substantial fraction of
MDS cases. Interestingly, the survival of patients in our study was
longer than those of prior studies that performed survival analysis,5,7
which showed a median survival of 43 to 50 months in patients with
favorable or normal karyotype without SNP-A abnormalities and
16 to 20 months in patients with additional SNP-A abnormalities. The
relatively increased OS seen in our cohort compared to prior studies
may potentially be attributed to either differences in patient popula-
tion, clinical practice, or a consequence of relatively smaller
cohort size.
The contribution of individual specific abnormalities to prognosis
also remains an area of future investigation. Our data suggest KMT2A-
PTD may be partially responsible for the poorer survival seen in MDS
patients, who otherwise might be classified as having lower risk dis-
ease, though a definitive determination is limited by the small number
of KMT2A-PTD. Additionally, two cases also identified CN-LOH as
additional anomalies on chromosome arms 7q and 11q, respectively,
which contain the genes EZH2 on 7q and CBL on 11q, both recur-
rently mutated in MDS with suggested adverse prognostic
impact.13-16 Consequently, the relative contribution of KMT2A-PTD
to prognosis requires further confirmation in larger sample study.
Because patients with additional SNP-A abnormalities have poorer
OS and relatively increased risk, the presence of these abnormalities
may potentially identify these patients as candidates for more urgent
therapeutic intervention including transplantation.
F IGURE 5 Genomic locations and graphic display of array results for KMT2A-PTD. Patient 7 had gain of 11q23.3 at the other homologue of
chromosome 11. KMT2A-PTD, KMT2A partial tandem duplication [Color figure can be viewed at wileyonlinelibrary.com]
772 CHOI ET AL.
While conventional karyotype continues as expected standard
practice in MDS diagnosis, the appropriate utilization of other related
ancillary testing to provide a comprehensive genetic assessment is an
important as-yet unresolved issue. For example, fluorescence in situ
hybridization (FISH) analysis can also detect additional abnormalities
outside of karyotype,17,18 however the National Comprehensive Can-
cer Network (NCCN) practice guidelines currently only recommend
FISH in cases where standard cytogenetics cannot be obtained.19 The
American Society for Clinical Pathology also supports a similar recom-
mendation.20 The European Society for Medical Oncology (ESMO)
practice guidelines slightly differ in this respect as they acknowledge a
potential benefit of FISH in cytogenetically normal cases and thus rec-
ommend FISH in the setting of normal karyotype.21 A similar algo-
rithm could potentially be applied with respect to SNP-A by focusing
its utilization in cases that would otherwise be designated of lower
risk. Recent studies have attempted to compare the relative detection
rates of abnormalities across different modalities and have confirmed
overall relatively higher resolution in SNP-A22 and next generation
sequencing platforms which complement standard cytogenetics and
FISH analysis.23 Outside of larger genomic alterations, the impact of
point mutations, which have also been implicated in survival of MDS
patients with further prognostic relevance,15,24 remains another area
for subsequent investigation. As clinical standard of care does not yet
include testing for point mutations, we were unable to ascertain their
significance in the context of additional SNP-A abnormalities, but this
is an area in which further analysis is warranted.
In conclusion, these findings demonstrate the potential prognostic
and therapeutic impact of the cytogenomic array, with particular util-
ity in MDS cases that would otherwise be classified as very low-
intermediate risk.
ORCID
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